These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14526202)

  • 1. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
    Boyd MA; Aarnoutse RE; Ruxrungtham K; Stek M; van Heeswijk RP; Lange JM; Cooper DA; Phanuphak P; Burger DM
    J Acquir Immune Defic Syndr; 2003 Oct; 34(2):134-9. PubMed ID: 14526202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Ndagijimana J; Verweel G; Hartwig NG; Niehues T; De Groot R; Burger DM
    J Acquir Immune Defic Syndr; 2005 May; 39(1):63-8. PubMed ID: 15851915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.
    Lee LS; Panchalingam A; Yap MC; Paton NI
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4476-8. PubMed ID: 15504888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD;
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
    Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
    J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Hoetelmans RM; Mulder JW; Schreij G; Hsu A; Lange JM; Beijnen JH; Meenhorst PL
    AIDS; 1999 Oct; 13(14):F95-9. PubMed ID: 10513637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
    Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
    Bergshoeff AS; Fraaij PL; van Rossum AM; Verweel G; Wynne LH; Winchell GA; Leavitt RY; Nguyen BY; de Groot R; Burger DM
    Antimicrob Agents Chemother; 2004 May; 48(5):1904-7. PubMed ID: 15105157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
    Mole L; Schmidgall D; Holodniy M
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):260-5. PubMed ID: 11464145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
    Cressey TR; Leenasirimakul P; Jourdain G; Tod M; Sukrakanchana PO; Kunkeaw S; Puttimit C; Lallemant M
    J Antimicrob Chemother; 2005 Jun; 55(6):1041-4. PubMed ID: 15883177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
    Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
    Hsu A; Granneman GR; Cao G; Carothers L; Japour A; El-Shourbagy T; Dennis S; Berg J; Erdman K; Leonard JM; Sun E
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2784-91. PubMed ID: 9797204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients.
    Aarnoutse RE; Brinkman K; Benetucci J; Begovac J; Stek M; Burger DM
    AIDS; 2004 Feb; 18(3):565-7. PubMed ID: 15090812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.